Is this the outcome people expected, not least after almost five years? It makes the sudden urgency that so many now demand very odd. Given that the current trajectory means no change for the vast majority of new therapies, why the urgency?
Helpful evidence of how the review is landing on outcomes to potentially benefit a few 'Unicorns'
June 1, 2026 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 31 July
July 31, 2026 - - Podcast -
New partnership aims to create national blueprint for earlier Alzheimer’s diagnosis and care
July 31, 2026 - - Latest News -
Industry associations still resisting non-disclosure agreements for negotiation
July 31, 2026 - - Latest News -
AUScelerate programs channel major investment into heart and diabetes innovations
July 30, 2026 - - Latest News -
New AusBiotech membership aims to help Australia’s early-stage life sciences founders thrive
July 30, 2026 - - Latest News -
CSL begins clinical trials to test higher-yield plasma manufacturing
July 30, 2026 - - Latest News -
AI will likely grow the HTA 'industrial complex', but it can also democratise the institution
July 30, 2026 - - Latest News

